[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"allergy-and-immunology\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:allergy-and-immunology":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,78,107,183],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100630543","shape-trial-skin-health-and-allergy-prevention-exposure-100630543",false,"NCT07489040","SHAPE Trial: Skin Health and Allergy Prevention Exposure","Multi-component Package for Skin Health and Allergen Exposure Strategy to Prevent Food Allergy","SHAPE","Inclusion Criteria:\n\n1. Healthy singleton, neonates born at term (gestational age ≥37 weeks) (e.g. newborn without complications such as severe respiratory conditions, major congenital abnormalities, severe inborn errors of immunity \\[e.g. severe combined immunodeficiency\\], severe neonatal infections, neurologic impairment, and major gastrointestinal disorders).\n2. The newborn has any or at least one of the following risk factors: is an only child (no live siblings); first-degree relatives (parents and\u002For siblings) with history of food allergy, allergic rhinitis\u002Fconjunctivitis, asthma, or atopic dermatitis.\n3. Parent(s)\u002Fguardian provided informed consent for the child's study participation.\n\nExclusion Criteria:\n\n1. Newborns born to mothers with positive routine prenatal screening for any of the vertically transmitted diseases (e.g. hepatitis B, hepatitis C, active syphilis or genital herpes simplex, Chlamydia trachomatis, gonorrhea and human immunodeficiency virus \\[HIV\\]) that may prevent adherence to any of the recommendations of the environmental packages.\n2. Inability to adhere to the study procedures, e.g. severe maternal conditions (e.g. eclampsia, life-threatening conditions requiring intensive care admission) or neonatal skin conditions that require specific care practices.\n3. Ongoing participation in another interventional study (e.g. trials involving skin care with topical creams, medication or interventions related to allergy prevention) that may interfere with the current study.\n4. No access to phone, internet, or email (requirements to contact participant\u002Fguardian).\n5. Planning to move out of the province within 12 months of study enrollment.","ALL","37 Weeks","42 Weeks",{"count":21,"type":22},64,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to determine if a multi-component environmental package (MEP) can prevent food allergies among infants at risk of developing food allergies in early life.\n\nResearchers will compare the multi-component environmental package to regular care to see if the MEP works to prevent food allergies. Participants will:\n\n* Be assigned to the multi-component environmental package or regular care once their baby is born\n* Complete a weekly diary\n* Attend in-office visits at 4 and 12 months of age\n* Complete web-based questionnaires at 4, 6, 9 and 12 months of age",[28],"Allergy and Immunology",[30,31,32,33],"Allergy","Allergy prevention","Skin health","Food allergy","NOT_YET_RECRUITING","2026-03-31",{"date":37,"type":38},"2026-04-06","ACTUAL",{"date":40,"type":22},"2026-04-01",{"date":42,"type":22},"2028-12-31",{"name":44,"class":45},"McMaster University","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100420209","feasibility-study-of-a-new-immunoglobulin-e-ige-assay-method-100420209","NCT04751760","Feasibility Study of a New Immunoglobulin E (IgE) Assay Method","Feasibility Study of a New Immunoglobulin E (IgE) Assay Method in Urine and Blood","LuLISA","Inclusion Criteria:\n\n* Males or females 6 months' old or older\n* Sensitization or allergy towards a trophallergen, an aeroallergen, hymenoptera venom or drug proven by:\n\n  * positive skin test (s)\n  * and \u002F or IgE specific (s)\\> 0.1 kUA \u002F L\n  * and \u002F or anamnesis in favor of an allergic reaction of mediated IgE\n* Social coverage up to date\n\nExclusion Criteria:\n\n* Children younger than 6 months'old\n* Children's weight less than 10 kg\n* Pregnant or breastfeeding women\n* Patients with cystic fibrosis\n* Patients with dysimmune or autoimmune pathology\n* Anamnesis in favor of a delayed allergy or a contact allergy.","6 Months","99 Years",{"count":58,"type":22},1376,"OBSERVATIONAL","The main objective is to study the feasibility of a new specific IgE assay using a bioluminescence technique in a pediatric and adult allergic population. For this, we will collect blood, and urine during a blood test scheduled for the follow-up of the patient.",[28],[63,64,65,66],"IgE assay","food allergy\u002F hypersensitivity","respiratory allergy\u002F hypersensitivity","hymenopter allergy\u002F hypersensitivity","RECRUITING","2026-03-16",{"date":70,"type":38},"2026-03-19",{"date":72,"type":38},"2021-04-20",{"date":74,"type":22},"2026-04-20",{"name":76,"class":45},"University Hospital, Toulouse",2,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":85,"sex":86,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":23,"phases":91,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":46},"100536140","expecting-mothers-study-of-consumption-or-avoidance-of-peanut-and-egg-100536140","NCT06260956","Expecting Mother's Study of Consumption or Avoidance of Peanut and Egg","ESCAPE","Inclusion Criteria:\n\n• o Subject must be able to understand and provide informed consent.\n\n* English-speaking adults, 18 years or older. (Spanish speaking adults may be included after consent document is translated and Spanish speaking study representatives are available to conduct and answer questions during informed consent process and for study follow up.)\n* Maternal consent must be provided for infants.\n* Pregnant women from the time pregnancy is confirmed until 27 weeks of gestation.\n* Self-reported at time of enrollment:\n\n  * no chronic inflammatory conditions that require long-term systemic immunosuppressive medications in first or second trimester\n  * carrying a fetus with a first-degree relative (i.e., mother, father, full sibling) with any self-reported or physician-diagnosed allergic disease (asthma, allergic rhinitis, atopic dermatitis, or food allergy).\n* Intend to give their infant their own breast milk for more than 3 months.\n* Can confidently say they have eaten PN and egg and have tolerated consumption with no food allergy reactions.\n* Willing to be randomized to consumption or avoidance diet.\n* Uncomplicated pregnancy (no gestational diabetes, no preeclampsia, no hyperemesis gravidarum), self-reported at time of enrollment.\n\nExclusion Criteria:\n\n* Inability or unwillingness of subject to give written informed consent or comply with study protocol.\n* Known history of renal\u002Fliver\u002Fcardiac insufficiency in the mother or infant.\n* Pregnant women with PN or egg allergy.\n* Pregnant women who refuse to eat PN (or peanut products) and\u002For eggs.\n* Physician diagnosed immunodeficiency in the mother or infant.\n* Current, diagnosed, mental illness or current, diagnosed, or self-reported, drug or alcohol abuse that, in the opinion of the investigator, would interfere with the subject's ability to comply with study requirements.\n* Past or current medical problems or findings from medical history that are not listed above, which, in the opinion of the investigator, may pose additional risks to the mother or infant from participation in the study, may interfere with the subject's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.",true,"FEMALE","18 Years","40 Years",{"count":90,"type":22},500,[25],"Peanut allergy is the most common cause of fatal and near-fatal food-allergic reactions and egg allergy is among the two most common causes of food-induced anaphylaxis. The proposed research will explore the development of sensitization to these food(s) in infants based on maternal consumption or avoidance during pregnancy and breastfeeding.",[28,94,95,96,97],"Peanut and Nut Allergy","Egg Allergy","Food Allergy in Infants","Food Allergy Peanut","2025-08-08",{"date":100,"type":38},"2025-08-13",{"date":102,"type":38},"2025-08-01",{"date":104,"type":22},"2029-09",{"name":106,"class":45},"University of Rochester",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":85,"sex":17,"minAge":115,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":118,"conditions":119,"keywords":144,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":46},"100469557","generation-victoria-cohort-2020s-a-statewide-longitudinal-cohort-study-of-victorian-children-and-their-parents-100469557","NCT05394363","Generation Victoria Cohort 2020s: A Statewide Longitudinal Cohort Study of Victorian Children and Their Parents","Generation Victoria Cohort 2020s. A Statewide Longitudinal Cohort of Victorian Children and Their Parents","GenV","Inclusion Criteria (Children):\n\n* Birth date between 4th October 2021 and 3rd October 2023\n* Live at the time of recruitment\n* Residing in Victoria at the time of recruitment\n* Has a legally acceptable representative capable of understanding the informed consent document and providing consent on the child's behalf, who provides a signed and dated informed consent form (e.g. a parent\u002Fguardian)\n\nInclusion Criteria (Adults):\n\n* Be a parent or guardian of a child who meets the eligibility criteria above\n* Provide a signed and dated informed consent form or have a legally acceptable representative capable of understanding the informed consent document and providing consent on the participant's behalf.\n\nExclusion criteria:\n\n* Children who are deceased at the time of recruitment (i.e. still born or died after birth) and their parents\u002Fguardians\n* Families unable to provide informed consent in any of the languages available","1 Day",{"count":117,"type":22},150000,"Generation Victoria (GenV) is a longitudinal, population-based study of Victorian children and their parents that will bring together data on a wide range of conditions ,exposures and outcomes. GenV blends study-collected, study-enhanced and linked data. It will be multi-purpose, supporting observational, interventional, health services and policy research within the same cohort. It is designed to address physical, mental and social issues experienced during childhood, as well as the antecedents of a wide range of diseases of ageing. It seeks to generate translatable evidence (prediction, prevention, treatments, services) to improve future wellbeing and reduce the future disease burden of children and adults.\n\nThe GenV Cohort 2020s is open to all children born over a two-year period, and their parents, residing in the state of Victoria Australia. The GenV Cohort 2020s is preceded by an Advance Cohort of children born between 5 Dec 2020 and 3 October 2021, and their parents. This comprises all families recruited at GenV's Vanguard hospital (Joan Kirner Women's and Children's) and at birthing hospitals throughout Victoria as GenV scaled up to commence recruiting for the GenV Cohort 2020s. The Advance Cohort have ongoing and full participation in GenV for their lifetime unless they withdraw but may have less complete data and biosamples.",[120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,28,142,143],"Mental Health","Child Wellbeing","Infant Health","Child Health","Reproductive Health","Healthy Aging","Health Equity","Quality of Life","Social Determinants of Health","Environmental Exposure","Genetics","Cognition","Learning","Child Development","Congenital Abnormalities","Disability","Injuries","Communicable Diseases","Noncommunicable Diseases","Physical Fitness","Diet","Obesity","Inflammation","Intergenerational Relations",[145,113,146,147,148,123,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,126,165,166,167,168,169,170,171,128,172,173],"Generation Victoria","Cohort Studies","Data Collection","Data Linkage","Midlife Health","Children","Infants","Family","Parents","Mothers","Fathers","Life course perspective","Population Health","Longitudinal Studies","Genetics, population","Demography","Epidemiology","Health Disparity","Minority Health","Vulnerable Populations","Clinical Trial","Randomized Controlled Trial","Pragmatic Clinical Trial","Health Services Research","Economic Models","Value of Life","Geographic Information Systems","Climate Change","Built Environment","2025-07-30",{"date":176,"type":38},"2025-08-03",{"date":178,"type":38},"2021-10-04",{"date":180,"type":22},"2033-10",{"name":182,"class":45},"Murdoch Childrens Research Institute",{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":17,"minAge":87,"maxAge":191,"enrollmentInfo":192,"targetDuration":115,"studyType":59,"phases":4,"briefSummary":194,"conditions":195,"keywords":198,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":46},"100464104","bern-human-organoid-study-to-study-host-microbe-interaction-100464104","NCT05323357","Bern Human Organoid-Study to Study Host-microbe Interaction","Establishment of Human Organoid Lines as a Tool to Dissect Molecular Pathways of Host-microbiota Interactions","humorg","Inclusion Criteria:\n\n* Signed informed consent\n* Indication for upper or lower endoscopic procedure\n* Ability to understand and follow study procedures and understand informed consent\n* Age 18-80 years\n* Negative pregnancy test result prior to study enrollment of female study participants (test will be performed prior to enrollment)\n* BMI between 18.5 and 30 kg\u002Fm2\n\nExclusion Criteria:\n\n* Disease known to chronically affect gut microbiota, gut epithelium or gut-associated immune system, namely inflammatory bowel disease, diverticulitis, microscopic colitis, liver cirrhosis, malignancy within the digestive tract, systemic sclerosis, coeliac disease, common-variable immunodeficiency, diabetes mellitus\n* Medication with immunosuppressants (e.g. corticoids, biological therapy)\n* Current diagnosis of a hematological disorder (e.g. anemia with hemoglobin \\\u003C7 g\u002Fdl, leukemia) or any other absolute contraindication for blood draw\n* Women who are pregnant\n* Serious coagulation disorder, relevant thrombocytopenia (\\\u003C50'000\u002Ful), double platelet-inhibition, oral anticoagulation (ASS therapy is possible)\n* Known or suspected non-compliance, drug, or alcohol abuse\n* Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc. of the participant\n* Previous enrolment into the current study\n* Enrolment of the investigator, his\u002Fher family members, employees, and other dependent persons\n* Inability or unwillingness to provide blood samples and tissue samples (biopsies)\n* Participants taking oral anticoagulant or with bleeding disorders who would be at much higher risk of bleeding after biopsy samples or who are contraindicated for an endoscopic examination\n* Patients unable to give informed consent\n* Patients that have been under antibiotic therapy in the last 4 weeks\n* Participation in other clinical study interfering with study procedures\n* Potential study participants that wish not to be informed about random results acquired during the study (e.g., during endoscopy or genetic analysis) relevant for their health and for prevention of diseases","80 Years",{"count":193,"type":22},100,"The human body inhabits a complex consortium of different microbes which together form the microbiota. Virtually every surface of the human body is colonized by a distinct microbiota, forming complex communities. An increasing number of research results indicates that changes in the microbiota can have vast effects on the health of its host.\n\nMost studies investigating the microbiota were conducted on animals, as many interventions and investigations cannot be performed on humans due to ethical considerations. This raises the question if findings from experimental studies are translational and can benefit patients. That becomes especially apparent when trying to dissect molecular mechanisms involved in this fine-tuned interplay between nutrients, the microbiota, and its host.\n\nBy establishing human organoid cultures from the large and small intestine that can be exposed to microbes and\u002For microbial products with subsequent transcriptomic, epigenetic and immunological analysis, the investigators aim to generate findings with high translational potential with new insights into the complex interaction of the microbiota, the host and its immune system.",[196,28,197],"Organoids","Microbiota",[199,200,201],"Enteroids","Host-Microbiota","Mucosal Immunology","2024-12-05",{"date":204,"type":38},"2024-12-11",{"date":206,"type":38},"2022-03-31",{"date":208,"type":22},"2026-03-30",{"name":210,"class":45},"Insel Gruppe AG, University Hospital Bern"]